Evidence map›Paper›PMID 32432040›Full record

ArticleFrontiers in oncology2020

FGFR2/STAT3 Signaling Pathway Involves in the Development of MMTV-Related Spontaneous Breast Cancer in TA2 Mice.

Jiaxing Du, Qi Zhao, Kai Liu, Zugui Li, Fangmei Fu, Kexin Zhang, Hao Zhang, Minying Zheng, Yongjie Zhao, Shiwu Zhang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Frontiers in pharmacology · 2022
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jiaxing DuGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Qi ZhaoDepartment of Pathology, Tianjin Union Medical Center, Tianjin, China.
Kai LiuDepartment of Pathology, Tianjin Union Medical Center, Tianjin, China.
Zugui LiGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Fangmei FuGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Kexin ZhangDepartment of Pathology, Tianjin Union Medical Center, Tianjin, China.
Hao ZhangGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Minying ZhengDepartment of Pathology, Tianjin Union Medical Center, Tianjin, China.
Yongjie ZhaoDepartments of General Surgery, Tianjin Union Medical Center, Tianjin, China.
Shiwu ZhangDepartment of Pathology, Tianjin Union Medical Center, Tianjin, China.
Tianjin People's Hospital · CNTianjin University of Traditional Chinese Medicine · CNTianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Tientsin Albino 2 (TA2) mouse has a high incidence of spontaneous breast cancer (SBC) in the absence of external inducers or carcinogens. The initiation of SBC is related to mouse mammary tumor virus (MMTV) infection and pregnancy. Pathologic analysis showed that breast cancer cells in TA2 mice are triple negative. Our previous study confirmed that fibroblast growth factor receptor 2 (FGFR2) expression increased in SBC tissue compared to that in their corresponding normal breast tissues of TA2 mice. The present study focused on the function of the FGFR2/STAT3 signaling pathway in the initiation of SBC. In this study, the expression of FGF3, FGFR2, STAT3, p-STAT3

Indexed as

FGFR2/STAT3MMTVspontaneous breast cancertientsin albino 2triple-negative breast cancer

Identifiers

PMID32432040
PMCPMC7214838
OpenAlexW3020838422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.